|
Type 4 Melanocortin Receptor
( MC4R )
The
type 4 melanocortin receptor ( MC4R ) sits on the surface of brain cells in
the
hypothalamus. It is activated by a-MSH which
comes from PMOC. Once a-MSH
is bound, the hypothalamus decreases the sensation of feeling hungry.
Defects in this receptor cause people to have increased appetites. They have no
other symptoms, unlike the rest of the genetic defects.
The increased appetite shows up by one year of age. They have
not only increased amount of fat, but also more lean mass and high bone
densities. Their growth in height is faster in childhood. As time goes on, these
symptoms seem to calm down. Adults are less hungry.
Up
to 5% of people with severe obesity have mutations in both copies of this gene
they received from their father and mother. 1%-2.5% of people with BMIs of more
than 30 have one copy of a mutated gene. This makes MC4R mutations the most
common obesity gene.
For the most part, these people are overweight. However,
there are some who have this genetic defect but are not obese. This means there
are other genetic and environmental factors that come into play. Additionally, a
certain genetic variations called V103I and I251L seem to reduce the risk of
becoming obese.
There is no current treatment for MC4R mutations. However,
since most of these people have one bad and one good gene, it is possible that
giving a drug that could stimulate the remaining good receptors could be a
medical therapy.

The hypothalamic leptin-melanocortin system
Return to Genetics or the
Home Page.
It is important you
discuss any weight loss or exercise plan with your doctor. Only you and
your physician can decide what is best for you. Some people have
certain conditions that prevent them from doing all exercises, and goal
body weights may be different for different people. You need to discuss
all these things with your physician before starting any weight loss or
exercise program.
This
article was written by
John
Vickery, MD.
References Fauci et al., Harrison's
Principles of Internal Medicine 17th ed., ch 74
Endocrine Reviews 27(7):710-718
Endocrinol Metab Clin N Am 2008;37:733-751
Current Opinion in Lipidology
2008;19:113-121

|